ASD - ETF AI Analysis
Top Page
Defiance Autism Impact ETF (ASD)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains over the year-to-date and past three months, showing positive momentum despite a recent one-month pullback.
Leading Holdings Showing Strength
Several of the largest positions, including Definium Therapeutics and other key health care names, have posted strong year-to-date gains that support the fund’s overall performance.
Global Diversification
Holdings spread across the U.S., Japan, the UK, Australia, and several other countries help reduce the impact of problems in any single market.
Negative Factors
High Sector Concentration in Health Care
With most of the portfolio in health care, the ETF is heavily exposed to swings in that single sector.
Small Asset Base
The fund manages a relatively low level of assets, which can make it more vulnerable to large investor inflows or outflows.
Above-Average Expense Ratio
The ETF’s expense ratio is on the higher side for an exchange-traded fund, which means more of the returns are used to cover fees.
ASD vs. SPDR S&P 500 ETF (SPY)
AUM1.36M
RegionNorth America
Expense Ratio0.79%
Beta0.14
IssuerDefiance
Inception DateJun 01, 2026
Dividend Yield0.02%
Asset ClassEquity
Index TrackedVettaFi Autism Impact Index - USD - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume132
30 Day Avg. Volume427
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
33.93Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering36
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ASD Summary
The Defiance Autism Impact ETF (ASD) is a health care–focused fund that follows the VettaFi Autism Impact Index. It invests in companies that support people on the autism spectrum and the broader neurodiverse community, including firms working on treatments, diagnostics, telehealth, and assistive technologies. Well-known holdings include AbbVie and BioMarin Pharmaceutical. Investors might consider ASD if they want growth potential in health care while also supporting autism-related causes, since part of the profits go to autism organizations. A key risk is that it is heavily concentrated in the health care sector, so its price can rise or fall more than the overall stock market.
How much will it cost me?This ETF has an expense ratio of 0.79%, which means you’ll pay about $7.90 per year for every $1,000 you invest. That’s higher than the average ETF because it’s a specialized, impact-focused fund that tracks a niche autism-related index rather than a broad, low-cost market index.
What would affect this ETF?ASD could benefit if demand grows for autism-related health services, telehealth, and innovative treatments, especially as U.S. healthcare spending and support for neurodiversity and impact investing continue to rise, helping many of its specialized holdings. On the other hand, it could be hurt by changes in healthcare regulations or reimbursement, setbacks in drug development for companies like Eli Lilly, Jazz Pharmaceuticals, or Teva, or a broad downturn in the U.S. health care sector that would weigh on its concentrated portfolio.
ASD Top 10 Holdings
ASD is powered by a bench of health-care names, with Revvity and Repligen acting as key engines thanks to their rising momentum and growth stories in diagnostics and life-science tools. Lifestance Health is also climbing steadily, reflecting investor interest in behavioral and mental health services. On the flip side, Definium Therapeutics has been lagging, reminding investors that early-stage biotech can be a bumpy ride, while ACADIA and Neuren show more mixed, stop-and-go progress. Overall, the fund is firmly anchored in health care with a mostly U.S.-centric, developed-market tilt.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Definium Therapeutics | 3.88% | $52.99K | $5.21B | 311.74% | 40 Neutral | |
| Neuren Pharmaceuticals Limited | 3.81% | $51.92K | AU$2.62B | 44.19% | 78 Outperform | |
| Lifestance Health Group | 3.55% | $48.40K | $4.80B | 135.50% | 61 Neutral | |
| Revvity | 3.51% | $47.83K | $16.01B | 66.44% | 67 Neutral | |
| Repligen | 3.24% | $44.19K | $9.98B | 43.49% | 68 Neutral | |
| Otsuka Holdings Co | 3.17% | $43.28K | ¥5.84T | 65.67% | 78 Outperform | |
| ACADIA Pharmaceuticals | 3.11% | $42.38K | $4.70B | 7.60% | 75 Outperform | |
| Sumitomo Dainippon Pharma Co | 2.86% | $38.99K | ¥722.01B | -15.46% | 66 Neutral | |
| BioMarin Pharmaceutical | 2.83% | $38.66K | $12.38B | 18.76% | 75 Outperform | |
| AbbVie | 2.83% | $38.55K | $466.45B | 18.82% | 66 Neutral |
ASD Technical Analysis
Neutral
―
Price Trends
27.43
Negative
Market Momentum
-0.10
Positive
47.07
Neutral
56.92
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ASD, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 27.56, equal to the 50-day MA of 27.43, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 47.07 is Neutral, neither overbought nor oversold. The STOCH value of 56.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ASD.
ASD Peer Comparison
Comparison Results
Performance Comparison
ASD
Defiance Autism Impact ETF
27.28
2.67
10.85%
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
PBJ
Invesco Dynamic Food & Beverage ETF
―
―
―
RSPR
Invesco S&P 500 Equal Weight Real Estate ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
TRUH
VanEck Healthcare TruSector ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents